161 related articles for article (PubMed ID: 38456403)
21. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice.
Kimura Y; Fukuda A; Ogawa S; Maruno T; Takada Y; Tsuda M; Hiramatsu Y; Araki O; Nagao M; Yoshikawa T; Ikuta K; Yoshioka T; Wang Z; Akiyama H; Wright CV; Takaori K; Uemoto S; Chiba T; Seno H
Gastroenterology; 2018 Jul; 155(1):194-209.e2. PubMed ID: 29604291
[TBL] [Abstract][Full Text] [Related]
22. Imaging Brain Metastasis Patients With 18F-(2S,4R)-4-Fluoroglutamine.
Xu X; Zhu H; Liu F; Zhang Y; Yang J; Zhang L; Zhu L; Li N; Kung HF; Yang Z
Clin Nucl Med; 2018 Nov; 43(11):e392-e399. PubMed ID: 30179907
[TBL] [Abstract][Full Text] [Related]
23. Moderate alcohol intake promotes pancreatic ductal adenocarcinoma development in mice expressing oncogenic Kras.
Asahina K; Balog S; Hwang E; Moon E; Wan E; Skrypek K; Chen Y; Fernandez J; Romo J; Yang Q; Lai K; French SW; Tsukamoto H
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G265-G276. PubMed ID: 31760766
[No Abstract] [Full Text] [Related]
24. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
[TBL] [Abstract][Full Text] [Related]
25. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.
Khandakar GI; Satoh R; Takasaki T; Fujitani K; Tanabe G; Sakai K; Nishio K; Sugiura R
Cells; 2022 Feb; 11(4):. PubMed ID: 35203351
[TBL] [Abstract][Full Text] [Related]
26. Cell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma.
Lee AYL; Dubois CL; Sarai K; Zarei S; Schaeffer DF; Sander M; Kopp JL
Gut; 2019 Mar; 68(3):487-498. PubMed ID: 29363536
[TBL] [Abstract][Full Text] [Related]
27. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
28. A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.
Duan X; Zhang T; Feng L; de Silva N; Greenspun B; Wang X; Moyer J; Martin ML; Chandwani R; Elemento O; Leach SD; Evans T; Chen S; Pan FC
Cell Stem Cell; 2024 Jan; 31(1):71-88.e8. PubMed ID: 38151022
[TBL] [Abstract][Full Text] [Related]
29. Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis.
Khan I; Marelia-Bennet C; Lefler J; Zuberi M; Denbaum E; Koide A; Connor DM; Broome AM; Pécot T; Timmers C; Ostrowski MC; Koide S; O'Bryan JP
Small GTPases; 2022 Jan; 13(1):114-127. PubMed ID: 33949915
[No Abstract] [Full Text] [Related]
30. Dynamic PET/CT imaging of
Xu X; Zhu H; Liu F; Zhang Y; Yang J; Zhang L; Xie Q; Zhu L; Li N; Kung HF; Yang Z
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2280-2292. PubMed ID: 32166510
[TBL] [Abstract][Full Text] [Related]
31. Comparative evaluation of 18F-labeled glutamic acid and glutamine as tumor metabolic imaging agents.
Ploessl K; Wang L; Lieberman BP; Qu W; Kung HF
J Nucl Med; 2012 Oct; 53(10):1616-24. PubMed ID: 22935578
[TBL] [Abstract][Full Text] [Related]
32. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
[TBL] [Abstract][Full Text] [Related]
33. Targeting mTOR dependency in pancreatic cancer.
Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
35. mTORC1 and mTORC2 Converge on the Arp2/3 Complex to Promote Kras
Zhao Y; Schoeps B; Yao D; Zhang Z; Schuck K; Tissen V; Jäger C; Schlitter AM; van der Kammen R; Ludwig C; D'Haese JG; Raulefs S; Maeritz N; Shen S; Zou X; Krüger A; Kleeff J; Michalski CW; Friess H; Innocenti M; Kong B
Gastroenterology; 2021 Apr; 160(5):1755-1770.e17. PubMed ID: 33388318
[TBL] [Abstract][Full Text] [Related]
36. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.
Lieberman BP; Ploessl K; Wang L; Qu W; Zha Z; Wise DR; Chodosh LA; Belka G; Thompson CB; Kung HF
J Nucl Med; 2011 Dec; 52(12):1947-55. PubMed ID: 22095958
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic Assessment of
Grkovski M; Goel R; Krebs S; Staton KD; Harding JJ; Mellinghoff IK; Humm JL; Dunphy MPS
J Nucl Med; 2020 Mar; 61(3):357-366. PubMed ID: 31601700
[No Abstract] [Full Text] [Related]
38. Alanine and glycine conjugates of (2S,4R)-4-[
Zha Z; Ploessl K; Lieberman BP; Wang L; Kung HF
Nucl Med Biol; 2018 May; 60():19-28. PubMed ID: 29525446
[TBL] [Abstract][Full Text] [Related]
39. Identification of
Thein KZ; Biter AB; Banks KC; Duda AW; Saam J; Roszik J; Janku F; Skoulidis F; Heymach JV; Kopetz S; Meric-Bernstam F; Hong DS
JCO Precis Oncol; 2022 Jul; 6():e2100547. PubMed ID: 35862868
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.
Cheng DK; Oni TE; Thalappillil JS; Park Y; Ting HC; Alagesan B; Prasad NV; Addison K; Rivera KD; Pappin DJ; Van Aelst L; Tuveson DA
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34021083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
